Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Singapore Institute of Advanced Medicine Holdings Ltd. has entered into a key partnership with Australian biopharmaceutical company EnGeneIC to manufacture and distribute advanced anti-cancer products in Asia and develop cutting-edge cancer theranostics. Under this strategic alliance, EnGeneIC will establish a manufacturing plant in Singapore and lead clinical trials, while the Singaporean company secures exclusive distribution rights in 17 Asian countries. Joint efforts will focus on leveraging EnGeneIC’s proprietary technology to advance cancer treatment and share profits from the sales of these innovative products.
For further insights into SG:9G2 stock, check out TipRanks’ Stock Analysis page.